DOCSLIB.ORG

Immunization Data Submission and Response Guidelines. Version

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunization Data Submission and Response Guidelines. Version Immunization Data Submission and Response Guidelines Alberta Health Version 6.6 March, 2021 Superseded Alberta Health Immunization Data Submission and Response Guidelines March 2021 Table of Contents A. DATA SUBMISSION GUIDELINE ........................................................................................................ 1 1. INTRODUCTION ................................................................................................................................... 1 2. SUBMISSION FILE NAMING CONVENTION ............................................................................................ 2 3. SUBMISSION FILE STRUCTURE ............................................................................................................ 3 OVERVIEW .............................................................................................................................................. 3 RECORD DESCRIPTIONS .......................................................................................................................... 4 Version Record ................................................................................................................................................ 4 Header Record ................................................................................................................................................ 4 Patient Record ................................................................................................................................................. 4 Immunization Record ....................................................................................................................................... 5 Antigen Count Record...................................................................................................................................... 6 Not Immunized Record .................................................................................................................................... 7 Antigen Not Administered Record .................................................................................................................... 7 Footer Record .................................................................................................................................................. 7 4. SUBMISSION TYPE USAGE .................................................................................................................. 8 RULES FOR ADDING DATA ....................................................................................................................... 8 RULES FOR DELETING DATA .................................................................................................................... 8 RULES FOR CHANGING DATA ................................................................................................................... 8 5. DATA ELEMENTS .............................................................................................................................. 10 VERSION RECORD ................................................................................................................................ 11 Record Type .................................................................................................................................................. 11 DSG Version Number .................................................................................................................................... 11 HEADER RECORD ................................................................................................................................. 12 Record Type .................................................................................................................................................. 12 Submitter Prefix ............................................................................................................................................. 12 Batch Number ................................................................................................................................................ 14 PATIENT RECORD ................................................................................................................................. 15 Record Type .................................................................................................................................................. 15 Record Number ............................................................................................................................................. 15 Unique Lifetime Identifier (ULI) ...................................................................................................................... 15 Provincial Health Number Type ..................................................................................................................... 16 Provincial Health Number .............................................................................................................................. 16 Alternate Person Identifier Type .................................................................................................................... 17 Alternate Person Identifier ............................................................................................................................. 17 Last Name ..................................................................................................................................................... 17 Given Name ................................................................................................................................................... 18 Middle Name .................................................................................................................................................. 18 Address Type ................................................................................................................................................. 18 Street Address 1 ............................................................................................................................................ 18 Street Address 2 ............................................................................................................................................ 19 Street Address 3 ............................................................................................................................................ 19 Street Address 4 ............................................................................................................................................ 19 City Name ...................................................................................................................................................... 19 Province Code ............................................................................................................................................... 20 Country Code ................................................................................................................................................. 20 Postal Code ................................................................................................................................................... 25 Quarter Section Code .................................................................................................................................... 26 Section ................................Superseded........................................................................................................................... 26 Township ....................................................................................................................................................... 26 Range ............................................................................................................................................................ 27 Meridian ......................................................................................................................................................... 27 Birth Date ....................................................................................................................................................... 27 Gender Code ................................................................................................................................................. 28 Homeless/Indigent Flag ................................................................................................................................. 28 IMMUNIZATION RECORD ........................................................................................................................ 29 Record Type .................................................................................................................................................. 29 Record Number ............................................................................................................................................. 29 Unique Lifetime Identifier (ULI) ...................................................................................................................... 29 ________________________________________________________________________________________________________ © 2021 Government of Alberta Alberta Health Immunization Data Submission and Response Guidelines March 2021 Submission Type ..........................................................................................................................................
Load more

Recommended publications
  • Maternal Vaccines - Safety in Pregnancy
    Journal Pre-proof Maternal Vaccines - Safety in pregnancy Dr Mala Arora, FRCOG (UK), FICOG, DObst (Ire), Chairperson, Vice President, Director, Consultant, Dr Rama Lakshmi, MBBS, MD PII: S1521-6934(21)00017-1 DOI: https://doi.org/10.1016/j.bpobgyn.2021.02.002 Reference: YBEOG 2112 To appear in: Best Practice & Research Clinical Obstetrics & Gynaecology Received Date: 14 August 2020 Revised Date: 18 November 2020 Accepted Date: 6 February 2021 Please cite this article as: Arora M, Lakshmi R, Maternal Vaccines - Safety in pregnancy, Best Practice & Research Clinical Obstetrics & Gynaecology, https://doi.org/10.1016/j.bpobgyn.2021.02.002. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Ltd. Maternal Vaccines - Safety in pregnancy Dr Mala Arora FRCOG (UK),FICOG, DObst (Ire) Chairperson ICOG 2017 Vice President FOGSI 2011 Director Noble IVF Centre, sector 14, Faridabad Consultant Fortis La Femme, GK2 New Delhi India Dr Rama Lakshmi MBBS,MD Fellowship (IVF &Reproductive Medicine) Milann Fertility Centre Bengaluru India Corresponding author: Dr Mala Arora E-mail: [email protected];Journal [email protected] Pre-proof Abstract Vaccination during pregnancy is important for active immunity of the mother against serious infectious diseases, and also for passive immunity of the neonate to infectious diseases with high morbidity and mortality.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • ANNUAL REPORT 2009 - 2010 from the Director
    School of Pharmacy ANNUAL REPORT 2009 - 2010 From the Director I am very pleased to present Memorial University’s School of Pharmacy 2009- 2010 annual report. This report provides an overview of how our program is affecting the future of health care in Newfoundland and Labrador and shows our appreciation to our alumni, friends and corporate partners who make this possible. For over 20 years, the School has been growing as a place of innovation, creativity and excellence in pharmacy education. Since 1989, we have graduated 702 students. We are proud to know that they now work in every corner of our province and country, as well as around the world, in all aspects of pharmaceutical practice and research. Our need to continue this growth is spurred by a regional urgency for more pharmacists in our health care system. During the past year we have been engaged in a number of activities as we plan to increase student enrolment. The lack of physical facilities to accommodate larger classes and faculty and staff present unique challenges. In their 2009 review, the Canadian Council for Accreditation of Pharmacy Programs identified the School’s growth is at risk due to inadequate space and facilities. We will continue to work with government to address this challenge, expand the program and satisfy the requirement for more pharmacy graduates to help meet the health care needs of Newfoundlanders and Labradorians. I am extremely proud of the accomplishments of our faculty, staff and students and I am glad you are taking the time to review this report.
    [Show full text]
  • Adverse Events Following Immunization Data Submission and Response Guidelines Adverse Events Following Immunization
    Alberta Alberta Health Health Adverse Events Following Immunization Data Submission and Response Guidelines Adverse Events Following Immunization Data Submission and Response Guidelines Version 6.7 September 2018 Version 6.4 SupersededDecember 2015 Alberta Health Adverse Events to Immunization Data Submission Guidelines September 2018 Document Revisions Version Date Revision Description 6.7 September 2018 Submitter Prefix Codes(Table 2) • 33 - Workplace Health and Safety – AHS • 34 - Workplace Health and Safety – Covenant Health • 45 - Fort McKay First Nation • 46 – Alexis First Nation • 47 – Beaver First Nation • 48 – Lubicon Lake Nation Vaccine Codes (Table 33) Added Vaccine Codes: • Var-SI Shingles Inactivated • MenB FHbp Meningococcal B FHbp (recombinant) Changed description of Var-S vaccine Changed description of Vaccine Codes • Var-S Shingles Live • RSVIg Respiratory Syncytial Virus • Meningococcal B (4C, OMV recombinant, absorbed) Delivery Management Site Codes (Table 27) • 195 - Workplace Health and Safety – AHS • 196 - Workplace Health and Safety – Covenant Health • 320 - Safeway 8863 (St. Albert) • 321 - Safeway 8830 (Airdrie) • 322 - Safeway 8897 (Spruce Grove) • 323 - Safeway 8886 Callingwood (Edmonton) • 324 – Safeway 8912 Garrison Woods (Calgary) • 325 - Safeway 8877 Red Deer • 326 – Safeway 8894 (Fort Saskatchewan) • 327 – Safeway 8885 (Stoney Plain) • 328 - Safeway 8842 (Glenmore Landing) • 329 - Discovery Ridge Compounding Pharmacy & Travel Clinic • 856 - Fort McKay Health Centre • 857 – Alexis Health Services • 858 –
    [Show full text]
  • Annual Report 2018
    ANNUAL REPORT 2018 PATIENT FOCUSED PHARMACY PRACTICE 1 TABLE OF CONTENTS Message from the Chair and Registrar 1 About the Board 2 Meet the New Board Members 3 Board Members 4 Board Committees 5 Quality Assurance Program 7 Practice Site Assessments 8 Registrant Based Activities 9 Licensing and Registration 10 Addressing Practice Concerns 11 Professional Practice Development 12 Communications 13 Minutes of 2018 Annual General Meeting 14 2018 Summarized Financial Statements 16 MESSAGE FROM THE CHAIR AND REGISTRAR It is with great pleasure we present the In 2018, great strides were made in the 2018 Annual Report for the Newfoundland development of new and updated standards and Labrador Pharmacy Board (NLPB). We and policies to guide our registrants in had a productive year of activities in each optimization of patient-focused pharmacy of our four business lines: registration and care. In response to the increased licensing, quality assurance, professional government action taken to reduce and practice, and complaints and discipline. prevent opioid related harms we further enriched our direction, education and Throughout the year we conducted business resources for pharmacy professionals as usual keeping our core values top of mind on the importance of providing Opioid while working to advance pharmacy care Agonist Maintenance Treatment. Other new for a safe and healthy community. Our goals additions include an interpretation guide on and objectives are strategically developed Ending the Pharmacist-Patient Relationship, in advance of the year ahead so that we are and a practice policy on Registrant Use of accountable to the people of the province. Social Media. Our annual outlook is aligned to best ensure our registrants are providing safe and quality As the scope of pharmacy practice continues Colleen Squires, Board Chair pharmacy care in accordance with the to grow, the regulatory processes to ensure Pharmacy Act, 2012, its Regulations, By-Laws safe and quality practice increase also.
    [Show full text]
  • New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination
    International Journal of Vaccines and Vaccination New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination Abstract Research Article Vaccines are being under investigation for the possible side effects they can Volume 4 Issue 1 - 2017 cause. In order to supply new information, an electron-microscopy investigation method was applied to the study of vaccines, aimed at verifying the presence of solid contaminants by means of an Environmental Scanning Electron Microscope equipped with an X-ray microprobe. The results of this new investigation show 1 the presence of micro- and nanosized particulate matter composed of inorganic National Council of Research of Italy, Institute for the Science elements in vaccines’ samples which is not declared among the components and and Technology of Ceramics, Italy 2International Clean Water Institute, USA 3Nanodiagnostics srl, Italy of those particulate contaminants have already been verified in other matrices whose unduly presence is, for the time being, inexplicable. A considerable part and reported in literature as non biodegradable and non biocompatible. The *Corresponding author: Dr. Antonietta Gatti, National evidence collected is suggestive of some hypotheses correlated to diseases that Council of Research of Italy, c/o Nanodiagnostics are mentioned and briefly discussed. Via E. Fermi, 1/L, 41057 San Vito (MO), Italy, Tel: 059798778; Email: Keywords: Vaccine; Disease; Contamination; Protein corona; Biocompatibility; Received: November 30, 2016 | Published: January 23, process; Quality control 2017 Toxicity; Nanoparticle; Immunogenicity; Foreign body; Environment; Industrial Introduction diseases [10,11]. Neurological damages induced in patients under hemodialysis treated with water containing Aluminum are Vaccines are one of the most notable inventions meant to reported in literature [12].
    [Show full text]
  • Artículos Científicos
    Editor: NOEL GONZÁLEZ GOTERA Número 183 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 110415 -170415 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS Publicaciones incluidas en PubMED durante el período comprendido entre el 11 y el 17 de abril de 2015. Con “vaccin*” en título: 154 artículos recuperados. Vacunas meningococo (Neisseria meningitidis) 2. Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil. Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, Cruz AC, Pereira- Manfro W, de Oliveira RH, Abreu TF, Hofer CB. Pediatr Infect Dis J. 2015 May;34(5):e113-e118. PMID: 25876102 Related citations Select item 25875985 18. Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. Tirani M, Meregaglia M, Melegaro A. PLoS One. 2015 Apr 13;10(4):e0123383. doi: 10.1371/journal.pone.0123383. eCollection 2015. PMID: 25874805 Related citations Select item 25874777 19. Effectiveness of Meningococcal C Conjugate Vaccine in Salvador, Brazil: A Case-Control Study. 1 Cardoso CW, Ribeiro GS, Reis MG, Flannery B, Reis JN. PLoS One. 2015 Apr 13;10(4):e0123734. doi: 10.1371/journal.pone.0123734. eCollection 2015. PMID: 25874777 Related citations Select item 25874726 83. Brazilian meningococcal C conjugate vaccine: Scaling up studies. Bastos RC, de Souza IM, da Silva MN, Silva FP, Figueira ES, Leal ML, Jessouroun E, Junior JG, Medronho RA, da Silveira IA. Vaccine. 2015 Apr 9. pii: S0264-410X(15)00427-2.
    [Show full text]
  • Employee Handbook Barrington Passage Pharmacy Ltd
    Employee Handbook Barrington Passage Pharmacy Ltd. Barrington Passage Pharmacy Ltd. Introduction: This Employee Handbook has been prepared as an information resource to confirm the policies and procedures that pertain to the normal business operation of Barrington Passage Pharmacy Ltd. and the philosophy and standards by which we operate. All employees must read and observe the policies and procedures described in this book. The Owners/ Management are committed to following these policies and procedures but reserve the right to take alternative steps if deemed necessary to manage the workplace. This is a working document and the Owner/Management reserve the right to change these policies at any time. Revisions to this Handbook will be done so in writing. Due to the nature of the Dispensary Operations, some policies and procedures may be different for Pharmacy staff and may be included in a separate document. All employees will be required to read the Handbook then sign the Acknowledgement Form upon initial receipt of this document to confirm that they have done so. At any time if you have any questions, concerns or comments, you should not hesitate to speak to your supervisor. Sincerely, Kim Geldart, PhC. Owner 2 Table of Contents Topic Page Last Updated Store Information Welcome to Pharmasave Workplace 4-11 January 2017 Policies and Procedure 12 January 2017 Probation Period 13 January 2017 Performance Review 14 January 2017 Pay Schedule 15 January 2017 Overtime Pay 16 January 2017 Work Schedules 17 January 2017 Holiday Pay 18 January
    [Show full text]
  • Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013
    Morbidity and Mortality Weekly Report Weekly / Vol. 64 / No. 11 March 27, 2015 Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013 Anne G. Wheaton, PhD1, Timothy J. Cunningham, PhD1, Earl S. Ford, MD1, Janet B. Croft, PhD1 (Author affiliations at end of text) Chronic obstructive pulmonary disease (COPD) is a group a random-digit–dialed telephone survey (landline and cell of progressive respiratory conditions, including emphysema phone) of noninstitutionalized civilian adults aged ≥18 years and chronic bronchitis, characterized by airflow obstruction that includes various questions about respondents’ health and and symptoms such as shortness of breath, chronic cough, risk behaviors. Response rates for BRFSS are calculated using and sputum production. COPD is an important contributor standards set by the American Association of Public Opinion to mortality and disability in the United States (1,2). Healthy Research Response Rate Formula #4.† The response rate is the People 2020 has several COPD-related objectives,* including number of respondents who completed the survey as a pro- to reduce activity limitations among adults with COPD. To portion of all eligible and likely eligible persons. The median assess the state-level prevalence of COPD and the associa- survey response rate for all states, territories, and DC in 2013 tion of COPD with various activity limitations among U.S. was 46.4%, and ranged from 29.0% to 60.3%. Additional adults, CDC analyzed data from the 2013 Behavioral Risk information is presented in the BRFSS 2013 Summary Data Factor Surveillance System (BRFSS). Among U.S. adults in Quality Report.§ all 50 states, the District of Columbia (DC), and two U.S.
    [Show full text]
  • PAM2021 Commstoolkit Final.Pdf
    1 Contents About PAM 3 10 ways to get involved 4 Key messages 6 Email & newsletter template 7 #MyFavePharm Contest 8 Celebrate your pharmacy team 9 Social media posts 10 Graphics 14 Printable material 16 2 About PAM Each March we celebrate the contributions that pharmacy professionals make to our health-care system and help educate Canadians about the health-care services and advice their pharmacists are now delivering. This year, we’ve put a new spin on things. Pharmacy Awareness Month has moved from ‘awareness’ to ‘appreciation’ to better reflect and celebrate the extraordinary role pharmacy professionals play in health care, especially during the COVID-19 pandemic. Join us in celebrating Pharmacy Appreciation Month this March! This toolkit This toolkit includes a range of information and resources to help you celebrate PAM and communicate your activities to your stakeholders, patients and the public. National and provincial pharmacy associations, pharmacy students and pharmacy professionals from across Canada will be celebrating PAM 2021 throughout March. Join the conversation and use some of these resources to get started. Visit pharmacists.ca/pam for more resources and information. About CPhA The Canadian Pharmacists Association (CPhA) is the uniting national voice of pharmacy and the pharmacist profession in Canada. As pharmacists undertake an enhanced role in the delivery of health care services, CPhA ensures that the profession is recognized as a national leader in health care, influencing the policies, programs, budgets and initiatives affecting the profession and the health of Canadians. More information is available at www.pharmacists.ca. Follow us: @CPhAAPhC @CPhA @cpha_aphc CPhATV 3 10 ways to get involved 1.
    [Show full text]
  • Vaccines in a Manner Not Approved by the U.S
    Immunization 101 Laurie Courtney MSN, RN Immunization Nurse Manager Massachusetts Department Of Public Health Immunization Division 1 MAIC 2021 Presenter Disclosure Information I, Laurie Courtney, have been asked to disclose any relevant financial relationships with ACCME-defined commercial entities that are either providing financial support for this program or whose products or services are mentioned during this presentation. I have no relevant financial relationships to disclose. I may discuss the use of vaccines in a manner not approved by the U.S. Food and Drug Administration, but in accordance with ACIP recommendations MAIC 2021 2 Outline • Principles of vaccination • 2021 Immunization schedules • Vaccination and the COVID-19 pandemic • Vaccine safety and adverse events reporting • COVID-19 guidance • Resources 3 MAIC 2021 Principles of vaccination 4 Community Immunity/Herd Immunity MAIC 2021 5 https://www.mlive.com/news/2014/12/how_do_vaccinations_work_the_s.html Types of Immunity • Passive Immunity . Produced by one animal or human and transferred to another . Immediate, temporary protection . Maternal antibodies . Blood products, IG, plasma . Antitoxin . Monoclonal antibodies • Active Immunity . Protection produced by a person’s own immune system . Lasts for many years, often for a lifetime . Survive infection . Vaccination https://www.vaccines.gov/basics/types 6 MAIC 2021 Types of Vaccines • Live-attenuated vaccines MMR, LAIV, Varicella, oral polio, rotavirus, BCG • Inactivated vaccines Hep A, IIV, IPV, rabies • Subunit, recombinant, polysaccharide, and conjugate vaccines PPSV23, PCV13, Hep B, MenACWY/B, Shingrix, HPV, Hib, Pertussis • Toxoid vaccines DTaP, Tdap, Td • Messenger RNA (mRNA) vaccines COVID-19 • Viral vector vaccines COVID-19 https://www.vaccines.gov/basics/types 7 MAIC 2021 Timing and Spacing of Vaccines • Refer to ACIP General Best Practice Guidelines .
    [Show full text]
  • Rubicon Pharmacies Is Seeking a Store Operator/Pharmacy Manager
    Rubicon Pharmacies is seeking a Store Operator/Pharmacy Manager to lead their team at Pharmasave #415 located in Biggar, SK! The store is open Monday to Friday from 8:30am to 7:00pm and Saturday from 9:00am to 5:00pm. This position will oversee the entire operation of Pharmasave #415. They will manage a staff of skilled pharmacists and pharmacy assistants. They will be a leader within the community and drive pharmacy services to better serve Biggar and its surrounding area. This position will ensure profitability through effective budgeting, inventory control and promotional activities. We offer competitive employment packages, including benefits & pension, and added incentives for certain markets. Rubicon strongly supports internal movement across and upward in our growing network. We believe in helping you achieve your career goals, while maintaining a healthy work-life balance at the same time. Rubicon is a growing company with over 100 locations throughout British Columbia, Alberta, Saskatchewan and Manitoba. Rubicon operates its stores within the Pharmasave, PharmaChoice, Value Drug Mart, Remedy’s RX and IDA franchise systems. We provide our teams with an extensive support network, and a variety of clinical programs, best-practices, and tools to succeed. Investing in innovations such as central-fill models and automated dispensing technology, allows local pharmacy teams more opportunity to focus on providing personalized, patient-centered care, while building adherence. Rubicon has embraced practice innovations and will continue developing programs and services to support our local pharmacy teams. JOB DESCRIPTION: STORE OPERATOR/PHARMACY MANAGER OBJECTIVE: This manager-level position is responsible for overseeing fulfillment functions to ensure the operation provides high quality care and customer service, and operates efficiently through optimisation of its human, physical, and financial capital within the framework of legislative requirements, and Rubicon policies and programs.
    [Show full text]